MAPK8 and neoplasm: Notably, in contrast to the marked inhibitory effect of in vivo JNK inhibition on the CSC/CSLC population within the tumors, the exactly identical SP600125 treatment protocol failed to have the slightest inhibitory effect on bulk tumor growth during the 10-day treatment period (Figure 3C).